The Effects Of Betastine And Cimetidine On Primary Liver Cancer And Expression Of Histamine Receptors MRNA Of Wistar Rats

Objective: To study the effects of betastine (BET) and cimetidine (CIM) on primary liver cancer (PLC) of wistar rats and the mRNA expression of histamine receptors in liver cancer tissue of wistar rats, and to find the new methods for the prevention and treatment of PLC, based on the theories about the histamine receptor agonist and antagonist as well as cytochrome P450 (CYP450). Methods: Dimethylamino-axobenzene (DAB) was used to induce the rat liver cancer model in order to observe the influences of BET and CIM on the content of CYP450, the bioactivities of glutathione S-transferase (GST), alpha-Fetoprotein (AFP) and α-L-fucosidase (AFU) of the serum indication of the PLC, and survival rate as well as hepatocarcinoma rate in rats. And semi-quantification reverse transcriptase-polymerase chase reaction (RT-PCR) was used to analyse the effects of CIM and BET on mRNA expression of histamine receptors in the tissue of hepatocarcinoma. Results:(1) During the experiment, the contents of CYP450 in BET group and CIM group maintained a low level and showed a tendency of decreasing.(2) The bioactivities of GST in BET group and CIM group increased slowly in the early stage and kept increasing later, but were lower than that in model group every stage before 32 weeks (p<0.01). (3) At 32 weeks, the survival rates of rats in each group were: 16.5% in model group,38.7% in BET group, and 45.2% in CIM group. (4) The hepatocarcinoma rates of rats in each group were: 68.7% in model group, 24.6% in BET group, and 21% in CIM group. (5)The contents of AFP(p<0.05) and the activities of AFU(p<0.01) in the BET group and CIM group were much lower than those in model group. (6) The level of relative mRNA expression of histamine H1 and H2 receptor in drug-treated groups and model group was significantly lower than that in the normal control group (p<0.01). The mRNA expressions of histamine H1 receptor in BET group and CIM group were notably higher than that in the model group (p<0.05). Conclusions: BET and CIM can decrease the content of CYP450 in rat, delay the increase of GST, decrease the content of AFP and the activity of AFU while relieving the liver injury in rat, increase the survival rate dramatically and reduce the hepatocarcinoma rate significantly. And BET and CIM can greatly reduce the decrease in the mRNA expression of H1 receptor during the occurrence and development of rat hepatocarcinoma.